p53 reactivator Rezatapopt synergizes with PI3Kα inhibitors to slow cancer growth in mice
adam_thiesen · x · 2026-11-09
Rezatapopt, a p53 reactivator, works synergistically with PI3Kα inhibitors to slow cancer growth both in vitro and in mouse models, suggesting a promising combination therapy strategy for p53-mutant tumors.
More from Research
- Meta teases entry into AI-for-science race, joining frontier labs push — kimmonismus · 2026-11-09
- Study: 3g Daily Creatine for 4 Weeks Improved Cognition in Women, Most in Older Adults — 2C_ornot2C · 2026-11-09
- Brynjolfsson, Korinek, Agrawal publish Economics of Transformative AI research agenda in CACM — erikbryn · 2026-11-09
- Researchers question AI capability acceleration: shift to RL may be the confounder — DavidSKrueger · 2026-11-09
- Neural network output layers explained: classification vs regression — HarperSCarroll · 2026-11-09
- Ropedia W0 trains robot world models on 10,000 hours of human video, lifting LIBERO-Plus by 6.76 points — jiqizhixin · 2026-11-09